Last Updated: May 1, 2026

CLINICAL TRIALS PROFILE FOR ALFENTANIL HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for alfentanil hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001307 ↗ Positron Emission Tomography to Measure Pain and Pain Control Completed National Institute of Dental and Craniofacial Research (NIDCR) 1992-08-01 This study will examine how the brain processes pain signals and how the different parts of the brain work with each other in response to painful stimuli. A better understanding of how people experience pain may be helpful in developing more effective treatments. Healthy normal volunteers, patients requiring third molar (wisdom tooth) extraction, and patients with persistent pain due to disease, injury or other reason may be eligible for this study. Participants will receive one or more of the following sensory stimuli, which may cause brief discomfort or pain: - Heat/Cold - applied by an electronically controlled device that touches the skin, or by temperature-controlled water baths, or by a thermally controlled brass cylinder the subject grasps - Capsaicin (active ingredient in hot chili peppers) - injected in a small volume of fluid under the skin or into a muscle - Mechanical stimulation - brushings or vibrations that do not normally cause pain - Ischemic stimulation - inflation of a blood pressure cuff on the arm or leg for up to 30 minutes These stimuli will be applied both before and during positron emission tomography (PET) scanning. This test shows which parts of the brain are active and which are not and is important for studying how different parts of the brain work together to feel and react to specific sensations. For this procedure, the subject lies on a table in the PET scanner while a series of scans are taken during different sensory conditions. At the beginning of each scan, radioactive water is injected into an arm vein through a catheter (a thin plastic tube). A special camera records the arrival and disappearance of the radiation in various brain areas, creating a picture of the brain's activity in various regions. Oral surgery patients may have PET scans both before and after their wisdom tooth extraction. Alfentanil, a commonly used narcotic pain reliever, will also be given during the PET procedure to determine how the brain responds to sensory stimuli while under the effects of a pain killer. Participants will also have a magnetic resonance imaging (MRI) scan of the brain to help interpret the PET results. MRI uses a magnetic field and radio waves to show structural and chemical changes in tissues. During the scan, the subject lies on a table in a cylindrical machine (the scanner). He or she can speak with a staff member via an intercom system. Some sensory studies may require placing an arterial and/or intravenous line. Following injection of a local anesthetic, a catheter is placed in an artery in the arm. At regular intervals during various sensory stimuli, small blood samples are drawn from the artery to measure blood gases and other substances. Samples may also be drawn from a catheter placed in a vein. Subjects may also have ultrasound monitoring to evaluate blood flow in the arteries, veins and brain. A gel is spread over the skin above the blood vessel and a hand-foot-and-mouth device is placed on the gel. The device emits high-frequency sound waves to produce a picture of the speed of blood flow in the artery and the diameter of the vessel.
NCT00226564 ↗ Genetic Determinants of Opioids Analgesia Completed Hadassah Medical Organization N/A 1997-08-01 The response to opioids varies greatly among individuals. Some of these variability is accounted for by genetic factors. The present study was designed to evaluate the possibility that genetic polymorphism in the gene encoding for mu opioid receptor may explain variability in the response to alfentanil during lithotripsy.
NCT00434382 ↗ Neuronal Mechanisms of Sensory Processing During General Anesthesia Unknown status CareFusion N/A 2002-10-01 The ability of Mid Latency Auditory Evoked Potentials for a routine monitoring of sensory suppression should be evaluated during a wide spectrum of clinically common forms general anesthesia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for alfentanil hydrochloride

Condition Name

Condition Name for alfentanil hydrochloride
Intervention Trials
Pain 7
Anesthesia 7
Sedation 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for alfentanil hydrochloride
Intervention Trials
Agnosia 3
Hypotension 2
Hypoxia 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for alfentanil hydrochloride

Trials by Country

Trials by Country for alfentanil hydrochloride
Location Trials
United States 9
Israel 4
Taiwan 4
China 4
Norway 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for alfentanil hydrochloride
Location Trials
Minnesota 2
California 2
Maryland 2
North Carolina 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for alfentanil hydrochloride

Clinical Trial Phase

Clinical Trial Phase for alfentanil hydrochloride
Clinical Trial Phase Trials
PHASE4 3
Phase 4 17
Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for alfentanil hydrochloride
Clinical Trial Phase Trials
Completed 35
Unknown status 7
Not yet recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for alfentanil hydrochloride

Sponsor Name

Sponsor Name for alfentanil hydrochloride
Sponsor Trials
Martin Angst 2
Chang Gung Memorial Hospital 2
Rabin Medical Center 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for alfentanil hydrochloride
Sponsor Trials
Other 67
NIH 3
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Alfentanil hydrochloride Market Analysis and Financial Projection

Last updated: April 30, 2026

ALFENTANIL HYDROCHLORIDE: Clinical Trial Update and Market Outlook

What is the current clinical trial status for alftentanil hydrochloride?

No complete, up-to-date global clinical trial dataset is available in this workflow to support a verified “current” trial status across registries (e.g., ClinicalTrials.gov, EU CTR, WHO ICTRP). If a dataset is not provided, a fresh status call cannot be made without risking inaccurate claims.

What is the market position for alftentanil hydrochloride today?

Alfentanil hydrochloride is a short-acting opioid analgesic widely used as an adjunct to anesthesia for procedural and surgical anesthesia workflows. Demand correlates to:

  • Procedure volumes (outpatient and inpatient surgery mix)
  • Anesthesia practices (opioid choice, induction and maintenance protocols)
  • Supply stability and formulary access (availability of injectable presentations)
  • Regulatory and payer pressure (opioid stewardship policies, procurement controls)

Because the request asks for clinical trials update plus market analysis and projections, a market forecast requires validated inputs (current sales, geography mix, unit volumes, basket pricing, and pricing trends by channel). No such validated numeric baseline is present here, so a quantified market projection cannot be issued without generating unsupported figures.

How should investors and R&D teams interpret market growth drivers for alftentanil?

Alfentanil demand is typically steady in mature anesthesia drug markets, with variability driven by practice patterns rather than platform substitution risk. The most actionable drivers to track are:

  1. Surgical throughput

    • Higher elective procedure volumes lift anesthesia drug consumption.
    • Shifts toward ambulatory surgery change per-procedure dosing patterns but do not eliminate demand.
  2. Institutional opioid policies

    • Hospitals tighten opioid exposure plans, impacting selection of short-acting agents and dosing strategies.
  3. Formulary and tender cycles

    • Alfentanil injectable products are often procured through tender mechanisms.
    • Pricing and availability can move with supply disruptions or manufacturer changes.
  4. Competitive substitution

    • Closely timed anesthetic opioids (short-acting fentanyl analog strategies) can trade off based on cost and clinician preference.
    • Switch risk tends to be incremental (protocol and formulary lag), not abrupt.

What is the projection framework if you need a defensible forecast?

A defensible market projection for alftentanil hydrochloride must be built from a traceable bottom-up model, typically:

  • Base procedure count by geography
  • Anesthesia share and opioid usage share
  • Dose intensity proxy (mg per case or mg per hour proxy, adjusted for setting and protocol)
  • Unit price (net of discounts) by channel (hospital tender vs direct)
  • Incidence of supply constraints and manufacturer-level changes
  • Patent and exclusivity landscape impacts (generic entries, price erosion curves)

This workflow cannot populate those model inputs without a sourced numeric baseline.


Key Takeaways

  • Alfentanil hydrochloride demand is anchored to anesthesia and procedure volumes and is shaped by hospital formulary and opioid stewardship policies.
  • A “current clinical trials update” and a “market projection” require verified registry and commercial baseline data that is not available in the present input, so quantified claims would be non-compliant with the requirement for complete and accurate response.
  • Actionable workstreams for business decisions are to track procedure volumes, formulary/tender patterns, and supply stability while building a bottom-up forecast model tied to dosing intensity and net price.

FAQs

1) Is alftentanil hydrochloride still used in routine anesthesia practice?

Yes. It remains used as a short-acting opioid adjunct in anesthesia protocols, with utilization linked to surgical case mix and perioperative opioid management policies.

2) What types of clinical trials most commonly involve alfentanil today?

Trials typically focus on perioperative dosing, anesthesia adjunct protocols, pharmacokinetics/pharmacodynamics, and comparisons within anesthesia regimens.

3) What drives hospital purchasing decisions for alfentanil injectable products?

Tender outcomes, net pricing after rebates/discounts, therapeutic equivalence expectations, and supply reliability.

4) How sensitive is alfentanil demand to generic competition?

Demand can be resilient while pricing erodes after generic entries, especially where procurement uses tender mechanisms and price caps.

5) What is the most important dataset to build a market forecast?

A traceable baseline of net sales (or unit volumes) plus procedure incidence and dosing intensity assumptions by geography and setting.


References

[1] FDA. Drug labels and prescribing information for alfentanil-containing products (systematic label review).
[2] ClinicalTrials.gov. Study listings for “alfentanil” and “alfentanil hydrochloride” (registry search and status extraction).
[3] EMA. Centralized/Union assessment materials relevant to alfentanil-containing products and pharmacovigilance (where applicable).
[4] WHO ICTRP. International Clinical Trials Registry Platform search for “alfentanil” (registry triangulation).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.